Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $326,509.26 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Intellia Therapeutics Stock Down 3.6 %

Shares of NTLA opened at $12.02 on Thursday. The company has a 50-day moving average price of $13.96 and a two-hundred day moving average price of $19.20. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -2.21 and a beta of 1.83. Intellia Therapeutics, Inc. has a 12 month low of $11.34 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.38) EPS. Equities research analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NTLA. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, November 18th. William Blair reaffirmed a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Wedbush reiterated a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. Finally, Chardan Capital raised their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently bought and sold shares of the business. Franklin Resources Inc. raised its position in Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the last quarter. Sanctuary Advisors LLC increased its stake in shares of Intellia Therapeutics by 147.9% in the third quarter. Sanctuary Advisors LLC now owns 53,590 shares of the company’s stock valued at $1,101,000 after buying an additional 31,976 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Intellia Therapeutics in the third quarter valued at about $417,000. Geode Capital Management LLC lifted its position in Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after buying an additional 49,367 shares in the last quarter. Finally, Barclays PLC grew its holdings in Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after acquiring an additional 44,022 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.